However, this cardiovascular disease benefit may be GLP‐1 mimetic specific, given that other trials using GLP‐1 mimetics with shorter half‐lives and lower homology to native GLP‐1, such as lixisenatide (ELIXSA) or exenatide (EXSCEL), failed to show a significant cardiovascular disease benefit (Holman et al., 2017). The gene discussed is GLP1R; the disease is cardiovascular disorder.